Drug
Mirdametinib
Mirdametinib: highest development phase Phase 1/2, developed by Merck. 6 trial records tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Mirdametinib NCT06159166 | Phase 1/2 | NF1 |
| Mirdametinib 2mg NCT05580770 | Phase 1/2 | Advanced Solid Tumor |
| Mirdametinib NCT07279233 | Phase 1 | Healthy |
| Mirdametinib NCT07840612 | Phase 1 | |
| Mirdametinib NCT07850635 | Phase 1 | Neurofibromatosis Type 1-Associated Plexiform Neurofibromas |
| Mirdametinib (MEK Inhibitor) NCT06997276 | Phase 1 | Healthy |
Latest
No recent events.
Follow Mirdametinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.